Dr Felix Olale is a partner and the global healthcare co-lead at LeapFrog Investments.
Felix combines deep expertise across the healthcare value chain with operational knowledge and commercial investment experience across America, Europe, Asia and Africa.
In his current role, Felix is responsible for fund design and strategy, origination, execution, value creation, portfolio management, exit and social impact across the LeapFrog healthcare portfolio. He led LeapFrog’s investments in Goodlife Pharmacies, MedGenome, Pyramid Pharma and Ascent Meditech.
Felix is a member of the LeapFrog board, and is also chairman of Goodlife Pharmacies and a director of MedGenome and Ascent Meditech. He previously served as vice chairman of the board of trustees for PATH, a leading health equity organisation and grantee of the Bill and Melinda Gates Foundation, and as a senior healthcare adviser to the International Finance Corporation.
After completing a Bachelor of Arts in molecular biology at the University of Pennsylvania, Felix received his doctorate in medicine from New York University (NYU) School of Medicine. He has also obtained a PhD in cellular biology from NYU. He began his career as a physician-scientist at the Skirball Institute of Biomolecular Medicine in New York, where he cloned two genes important for early organ development and regeneration. He also worked as a venture capital analyst at NYU’s Applied Research Support Fund, associate partner and leader in the pharmaceutical and medical products, and global health practices at McKinsey & Company, and executive chairman of the Excelsior Group, an adviser and investor in healthcare and technology companies.
Felix has published several peer-reviewed articles and is a regular speaker at global conferences. He is a co-founder of the MBA in healthcare management at Kenya’s Strathmore Business School, the first program of its kind in Africa.